Protocol Ledger

NCT06176352 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Interventional Phase III clinical trial protocol NCT06176352 sponsored by Roche / Genentech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-06 Enrollment: 280 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06176352
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)280 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06176352
Protocol FieldVerified Registry Value
NCT IdentifierNCT06176352
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment280 participants (ACTUAL)
Registered Start Date2024-03-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06176352
Hospital Research SiteLocationSite Profile
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing Tsinghua Changgung HospitalBeijing, ChinaOpen Hospital Dossier ->
The Second Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI